HDAC6 HDAC8 Selective Inhibitors Reducing Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors, particularly pan-HDAC inhibitors, exhibit broad spectrum activity but with non-specific cytotoxicity, limiting their clinical application, while specific isoform inhibitors like HDAC6 and HDAC8 show lower cytotoxicity but are less developed for certain cancer subtypes like neuroblastoma and multiple myeloma.
Innovation Solution
Development of compounds with rigid tetrahydronaphthylene and 1,2,3,4-tetrahydroquinoline linkers between zinc-binding hydroxamic acids and capping groups, demonstrating submicromolar to micromolar inhibition of HDAC6 or HDAC8, inducing apoptosis and cell differentiation with reduced p21 induction activity, suitable for neuroblastoma and multiple myeloma treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If pan-HDAC inhibitors are used, then broad spectrum anti-tumor activity is achieved, but non-specific cytotoxicity increases
Solution Approach 1:
The patent applies local quality by designing HDAC inhibitors with specific structural features (hydroxamic acid core combined with particular capping groups and linkers) that confer selective binding affinity to specific HDAC isoforms (HDAC6 and HDAC8) rather than binding all HDAC isoforms equally. This structural optimization enables the compound to exert anti-tumor activity specifically through HDAC6/HDAC8 inhibition while avoiding the non-specific cytotoxicity associated with pan-HDAC inhibitors.
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters of HDAC inhibitors, including the introduction of rigid tetrahydronaphthylene and 1,2,3,4-tetrahydroquinoline linkers, and optimization of capping groups. These structural parameter modifications result in submicromolar to micromolar inhibition of HDAC6 or HDAC8 with reduced off-target effects, thereby changing the binding specificity and cytotoxicity profile of the compounds.
2Object-affected harmful factors
If specific isoform inhibitors (HDAC6/HDAC8) are used, then non-specific cytotoxicity is reduced, but development for certain cancer subtypes is less advanced
Solution Approach 1:
The patent applies universality by designing a versatile class of HDAC6/HDAC8 selective inhibitors that can be applied across multiple cancer subtypes. The compound structure (formula I with various substituents R1-R4) provides a platform for treating different cancer types including neuroblastoma and multiple myeloma, which are specifically mentioned in the patent. The selective mechanism against HDAC6/HDAC8 enables effective treatment of cancers where these isoforms play critical roles, while maintaining low non-specific cytotoxicity.
3Reliability
If HDAC inhibitors are used to induce apoptosis, then tumor cell proliferation is inhibited, but p21 induction activity varies
Solution Approach 1:
The patent applies local quality by optimizing the molecular structure at specific positions to achieve selective HDAC6/HDAC8 inhibition that preferentially induces apoptosis through mechanisms independent of strong p21 induction. The hydroxamic acid core with specific capping groups and linkers creates a local binding interface that triggers apoptotic pathways directly, providing reliable apoptosis induction with variable p21 induction activity depending on the specific compound substitution.
Data Source
AI summary
The present invention provides a compound of formula (I)or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to processes for making said compounds and uses of said compounds, in particular their use as medicaments, more particularly their use as medicaments in the treatment of cancer.